Allogeneic human umbilical cord blood haematopoietic progenitor cell therapy(StemCyte)

StemCyte's Phase IIa trial of HPC, Cord Blood (HPC, CB) for Post-COVID syndrome shows significant improvement in fatigue symptoms.

The FDA has approved StemCyte's REGENECYTE, a hematopoietic progenitor cell therapy derived from umbilical cord blood, for certain hematopoietic system disorders.

The FDA has approved StemCyte's Biologics License Application for REGENECYTE, a cord blood stem cell therapy, marking a significant advancement in treating blood and immune system disorders.

The FDA has approved StemCyte's REGENECYTE, a cord blood stem cell therapy, for treating blood and immune system disorders.

The FDA has granted Biologics License Application approval to StemCyte for REGENECYTE, a cord blood stem cell therapy, marking a significant advancement in cell therapy.